xRead - September 2022

Wise et al.

Page 431

No difference in asthma scores or rescue salbutamol for all groups. PD 20 not

Author Manuscript Author Manuscript Author Manuscript Author Manuscript Study design Study groups Clinical endpoint Conclusion

No difference of all asthma symptoms with Bdp. PC 20 improved with Bdp. Evening asthma symptoms reduced with Bdp.

significantly different. FEV1 increased with FP and BDP in season 2.

Changes with Bdp INCS vs placebo: asthma symptoms reduced, decrease in rescue medication use, BHR reduced.

No difference of FeNO for MF INCS vs placebo. Nasal ECP reduced. No difference in PEF or FEV1.

Increased PEF for FP INCS + inhaled FP vs other groups. PEF increase for inhaled FP vs no inhaled FP. FEV1 higher with inhaled FP. Increased BHR with FP INCS; no increase with inhaled FP.

FP INCS improved nasal symptoms. No asthma outcome improvement with FP INCS addition to inhaled FP-salmeterol.

Reductions of AR and asthma symptoms in all groups. No change PEF or BHR. Increased FEV1 for inhaled Bdp. Asthma morbidity reduced for all.

Asthma and rhinitis symptoms, PC 20 , Bdp deposition b

Asthma and AR symptom scores, PEF, FEV1 and BHR (PC 20 ), proxy indicators of asthma-related morbidity

Asthma scores, rescue use of salbutamol, methacholine PD 20 , FEV1

(work absence, emergency department visits, etc.)

Rhinitis and asthma symptom scores, rescue medication use, BHR (histamine provocation)

FeNO, ECP in nasal lavage, PEF, FEV1

Asthma and AR symptoms, PFTs, methacholine BHR, PEF

Daily PEF, daily asthma and AR symptoms, rescue albuterol use

Stelmach et al. 1839 2005 1b DBRCT PAR and mild-to-moderate persistent asthma (n = 59): 1 Bdp INCS 400 μ g + inhaled placebo; 2 Placebo nasal spray and inhaled Bdp 1000 μ g; 3 Bdp INCS 400 μ g and inhaled 1000 μ g daily

1 FP INCS 200 μ g daily + inhaled FP 250 μ g BID;

Agondi et al. 1835 2008 1b DBRCT AR and asthma (n = 33): 1 Bdp INCS 400 μ g per day;

Thio et al. 1840 2000 1b DBRCT Two grass pollen seasons of treatment (season 1, n = 21; season 2, n = 67): 1 FP INCS 200 μ g daily; 2 Placebo nasal spray; 3 Bdp INCS 400 μ g Watson et al. 1811 1993 1b DBRCT, crossover 1 Bdp INCS 100 μ g twice daily, then placebo;

1 FP INCS 200 μ g;

2 Placebo nasal spray

Pedroletti et al. 1836 2008 1b DBRCT Perennial rhinitis and allergic asthma (n = 40): 1 MF INCS; 2 Placebo Dahl et al. 1837 2005 1b DBRCT, double dummy

2 FP INCS + inhaled placebo;

3 Intranasal placebo + inhaled FP; 4 Intranasal and inhaled placebo

2 Montelukast 10 mg; 3 Placebo.

Pollen-induced AR and asthma (n = 262):

SAR and persistent asthma (n = 863):

All received inhaled FP-salmeterol.

AR and controlled asthma (n = 21):

open-label

Study Year LOE

Nathan et al. 1838 2005 1b RCT, plus

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.